• Channels
    • All News
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Health Tech
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Nikkei Biotechnology
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • Editorial Standards
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP
  • LOG IN

Ot­su­ka and ICU Med­ical forge IV man­u­fac­tur­ing net­work to sup­ply the US

6 months ago
Deals
Manufacturing

Af­ter stock slides, Am­gen ad­dress­es bone den­si­ty talk on obe­si­ty drug

6 months ago
R&D
Pharma

TRexBio rais­es $84M to take in-house im­mune pro­gram in­to the clin­ic

6 months ago
Financing

Ex­clu­sive: Flag­ship names two CEO-part­ners to lead Va­lo Health, Apri­ori Bio

6 months ago
People
Startups

New can­cer class heats up as BioN­Tech buys out Chi­na part­ner and its PD-L1/VEGF drug

6 months ago
Deals
China

Sy­ros' shares plum­met as blood can­cer drug fails again

6 months ago
R&D

Pfiz­er look­ing to sell hos­pi­tal drugs unit — re­ports

6 months ago
Pharma

As­traZeneca CEO reaf­firms com­mit­ment to Chi­na fol­low­ing ex­ec­u­tive's de­ten­tion

6 months ago
China
Pharma

Syn­dax's menin in­hibitor suc­ceeds in piv­otal tri­al, but in­vestors aren't im­pressed

6 months ago
R&D
Pharma

Mer­ck, As­traZeneca tout Phase 3 win for can­cer-turned-rare dis­ease drug

6 months ago
R&D
Pharma

In­ter­cept is de­nied full FDA ap­proval for Ocali­va, but claims it will keep drug on mar­ket

6 months ago
Pharma
FDA+

'Ex­per­tise is a re­al thing': FDA com­mis­sion­er warns of po­lit­i­cal risk to agency

6 months ago
FDA+

Mer­ck KGaA plans Chi­na sub­mis­sion af­ter late-stage win for tu­mor drug

6 months ago
R&D
China

Apol­lo makes a deal worth up to $926M; Abeona re­sub­mits gene ther­a­py

6 months ago
News Briefing

Ex­clu­sive: GV-backed Med­ic­aid start­up Di­verge Health rais­es $52M

6 months ago
Financing
Health Tech

Up­dat­ed: As­traZeneca, Dai­ichi Sankyo re­place lung can­cer fil­ing for En­her­tu suc­ces­sor

6 months ago
R&D
Pharma

Bay­er not eye­ing new deals to ad­dress Xarel­to sales ero­sion

6 months ago
Pharma

As­traZeneca bud­gets an­oth­er $2B to boost man­u­fac­tur­ing and R&D in US

6 months ago
R&D
Manufacturing

Alen­tis nabs $181M to broad­en Claud­in's scope in AD­Cs

6 months ago
Financing
Startups

Roche teams with Flare Ther­a­peu­tics on tran­scrip­tion fac­tors

6 months ago
Startups
Deals

Maze's ALS spin­out Trace Neu­ro­science rais­es $101M for ALS and neu­ro work

6 months ago
Financing
Startups

Sanofi, Ope­nAI, For­ma­tion Bio de­but pa­tient re­cruit­ing tool, will use in Phase 3 mul­ti­ple scle­ro­sis stud­ies

6 months ago
R&D
AI

No­var­tis pays $150M up­front to Schrödinger in new drug deal, ramps up soft­ware use

6 months ago
Deals
R&D

GSK snags Parkin­son's drug from Flag­ship start­up Vesal­ius

6 months ago
Startups
Deals
First page Previous page 77787980818283 Next page Last page
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Health Tech
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Nikkei Biotechnology
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • Editorial Standards
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints News 2025

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
FT Specialist Logo
A service from the Financial Times